Page last updated: 2024-09-05

tolvaptan and Hypertension

tolvaptan has been researched along with Hypertension in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (12.50)	29.6817
2010's	12 (75.00)	24.3611
2020's	2 (12.50)	2.80

Authors

Authors	Studies
Ding, L; Gong, L; Jiang, W; Lu, J; Qian, X; Tang, W; Xie, F; Xu, M; Xu, W	1
Blais, JD; Chapman, AB; Cornec-Le Gall, E; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Harris, PC; Heyer, CM; Irazabal, MV; Le Meur, Y; Ouyang, J; Perrone, RD; Senum, SR; Torres, VE	1
Han, Q; Liu, M; Yang, J	1
Aonuma, K; Chiba, H; Ishizu, T; Namekawa, M; Sai, S; Seo, Y	1
Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T	1
Buehrer, BA; Cassell, MD; Davis, DR; Grobe, JL; Hilzendeger, AM; Ketsawatsomkron, P; Li, H; Littlejohn, NK; Liu, X; Pearson, NA; Pelham, CJ; Siel, RB; Sigmund, CD; Thompson, AP; Weidemann, BJ	1
Mager, DE; Mallikaarjun, S; Shoaf, SE; Van Wart, SA	1
Mei, C; Wüthrich, RP	1
Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H	1
Simms, RJ	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Ouyang, J; Perrone, RD; Torres, VE	1
Ghali, JK; Tam, SW	1
Steinman, TI	1
Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y	1
Streefkerk, JO; van Zwieten, PA	1
Balding, LC; Burrell, LM; Johnston, CI; Naitoh, M; Risvanis, J	1

Reviews

7 review(s) available for tolvaptan and Hypertension

Article	Year
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. International urology and nephrology, 2023, Volume: 55, Issue:3 Topics: Abdominal Pain; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Hematuria; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Polyuria; Tolvaptan	2023
Pharmacological management of polycystic kidney disease. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:8 Topics: Animals; Benzazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Tolvaptan; Treatment Outcome	2014
Autosomal dominant polycystic kidney disease. BMJ (Clinical research ed.), 2016, Feb-11, Volume: 352 Topics: Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Risk Factors; Tolvaptan	2016
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. Journal of cardiac failure, 2010, Volume: 16, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance	2010
Polycystic kidney disease: a 2011 update. Current opinion in nephrology and hypertension, 2012, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan	2012
Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. Autonomic & autacoid pharmacology, 2006, Volume: 26, Issue:2 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Drug Design; Heart Failure; Hormone Antagonists; Humans; Hypertension; Inappropriate ADH Syndrome; Indoles; Presynaptic Terminals; Pyrrolidines; Receptors, Vasopressin; Renal Artery; Sympathetic Nervous System; Synaptic Transmission; Tolvaptan; Vasoconstriction; Vasoconstrictor Agents	2006
Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension. Experimental physiology, 2000, Volume: 85 Spec No Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hypertension; Morpholines; Receptors, Vasopressin; Spiro Compounds; Tolvaptan	2000

Trials

3 trial(s) available for tolvaptan and Hypertension

Article	Year
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 04-01, Volume: 33, Issue:4 Topics: Adolescent; Adult; Age Factors; Antidiuretic Hormone Receptor Antagonists; Clinical Trials as Topic; Disease Progression; Female; Gene Rearrangement; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Severity of Illness Index; Tolvaptan; TRPP Cation Channels; Young Adult	2018
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:9 Topics: Adult; Antihypertensive Agents; Benzazepines; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Models, Biological; Renal Insufficiency; Tolvaptan; Young Adult	2013
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clinical journal of the American Society of Nephrology : CJASN, 2016, 05-06, Volume: 11, Issue:5 Topics: Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypernatremia; Hypertension; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pain; Polycystic Kidney, Autosomal Dominant; Severity of Illness Index; Tolvaptan	2016

Other Studies

6 other study(ies) available for tolvaptan and Hypertension

Article	Year
Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993), 2019, Volume: 41, Issue:4 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Hypertension; Kidney Medulla; Male; Methylamines; Osmolar Concentration; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tolvaptan; Vasopressins	2019
Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion. Hypertension research : official journal of the Japanese Society of Hypertension, 2019, Volume: 42, Issue:3 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Central Venous Pressure; Fibrosis; Heart Failure; Hemodynamics; Hypertension; Kidney Diseases; Kidney Medulla; Male; Protective Agents; Rats; Rats, Inbred Dahl; Sodium, Dietary; Stroke Volume; Tolvaptan; Ultrasonography; Vascular Resistance	2019
Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction. Clinical and experimental hypertension (New York, N.Y. : 1993), 2020, Volume: 42, Issue:2 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Hypertension; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan; Ventricular Dysfunction, Left	2020
Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. American journal of physiology. Regulatory, integrative and comparative physiology, 2013, May-15, Volume: 304, Issue:10 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Brain; Gene Expression; Hypertension; Hypothalamus; Mice; Mice, Transgenic; Receptors, Vasopressin; Renin-Angiotensin System; Tolvaptan; Vasopressins	2013
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure. Journal of cardiovascular pharmacology, 2015, Volume: 66, Issue:5 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling	2015
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circulation. Heart failure, 2012, Jul-01, Volume: 5, Issue:4 Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left	2012